Maxim Group Upgrades Telomir Pharmaceuticals (NASDAQ:TELO) to “Strong-Buy”

Telomir Pharmaceuticals (NASDAQ:TELO) was upgraded by Maxim Group to a “strong-buy” rating in a research note issued on Thursday, Zacks reports.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Telomir Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $4.00.

Telomir Pharmaceuticals Price Performance

Shares of NASDAQ TELO opened at $1.23 on Thursday. Telomir Pharmaceuticals has a 1-year low of $0.89 and a 1-year high of $2.09. The business has a fifty day moving average price of $1.15 and a 200 day moving average price of $1.25. The stock has a market capitalization of $84.60 million, a P/E ratio of -1.35 and a beta of -0.25.

Telomir Pharmaceuticals (NASDAQ:TELO) last posted its earnings results on Thursday, August 13th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.72).

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. OneDigital Investment Advisors LLC acquired a new position in shares of Telomir Pharmaceuticals in the second quarter valued at about $29,000. World Investment Advisors acquired a new stake in shares of Telomir Pharmaceuticals during the fourth quarter worth about $47,000. Bank of New York Mellon Corp acquired a new stake in shares of Telomir Pharmaceuticals during the second quarter worth about $66,000. Finally, BlackRock Inc. purchased a new stake in Telomir Pharmaceuticals in the second quarter valued at approximately $359,000.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing therapies for diseases and conditions associated with aging. The company’s research is centered on telomere biology, an area involving the protective structures at the ends of chromosomes that generally shorten as cells divide and age.

Telomir’s lead product candidate is TELOMIR-1, an orally administered small-molecule compound being investigated for its potential to address telomere shortening and support healthier cellular aging.